RNAi specialist Alnylam Therapeutics’ Amvuttra (vutrisiran) has been recommended for use on the National Health Service (NHS) in England as an option for treati 19 January 2023
Cost-effectiveness body the Institute for Clinical and Economic Review (ICER) has published its second annual Barriers to Fair Access assessment of prescription 18 January 2023
Large pharmaceutical firms are increasingly upset at the deal they agreed with the British government on drug pricing, the Voluntary Scheme for Branded Medicine 16 January 2023
Administrators at the US Department of Health and Human Services (HHS) have announced key dates in its planned negotiation of certain prescription drug prices a 12 January 2023
A draft report on amyloid beta-targeting antibodies in Alzheimer’s disease, prepared by the Boston, Massachusetts-based pricing watchdog the Institute for Clini 23 December 2022
Months after estimating that a fair US price for Pfizer’s Paxlovid (nirmatrelvir/ritonavir) would be between $3,600 and $5,800, the Institute for Clinical and E 21 December 2022
The Association of the British Pharmaceutical Industry (ABPI) has warned UK lawmakers that an existing pricing agreement is unsustainable, and that the cost of 15 December 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.